IGM Biosciences, Inc.
325 East Middlefield Road
Mountain View
CA
94043
United States
Tel: (650) 965-7873
Website: https://igmbio.com/
Email: info@igmbio.com
About IGM Biosciences, Inc.
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we plan to initiate a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is expected to be an IgM antibody targeting Death Receptor 5 (DR5).
52 articles with IGM Biosciences, Inc.
-
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
12/1/2022
IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST.
-
IGM Biosciences to Present at Three Upcoming Investor Conferences - November 08, 2022
11/8/2022
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences.
-
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update
11/3/2022
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent developments.
-
IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update
8/8/2022
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent developments.
-
IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference
6/1/2022
IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 3:00 p.m. EST in New York.
-
IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare Conference
5/10/2022
IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 9:30 a.m. EST in New York.
-
IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update
5/9/2022
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent developments.
-
IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi$150 Million Payment to IGM from Sanofi
5/6/2022
IGM Biosciences, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), has expired in connection with the Company’s previously announced exclusive worldwide collaboration agreement with Sanofi.
-
IGM Announces Closing of $230.0 Million Public Offering
4/6/2022
IGM Biosciences, Inc. announced the closing on April 1, 2022 of its previously announced underwritten public offering of 8,695,653 shares of its non-voting common stock and, pursuant to the exercise in full by the underwriters of a 30-day option to purchase additional shares, 1,304,347 shares of its voting common stock, each at a price to the public of $23.00 per share.
-
Money on the Move: March 23-29
3/30/2022
This week, money moved in the form of equity financing, upfront partnership payments, nonprofit donations and federal funding. -
IGM Announces Pricing of $200.0 Million Public Offering
3/30/2022
IGM Biosciences, Inc. announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting common stock at a price to the public of $23.00 per share.
-
Sanofi and IGM Biosciences inked a collaboration deal for oncology, immunology and inflammation that could surpass $6 billion.
-
Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
3/29/2022
Sanofi and IGM Biosciences, Inc. announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets.
-
IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with Sanofi
3/29/2022
IGM Biosciences, Inc. announced that the Company will host a conference call and live audio webcast, Tuesday, March 29, 2022, at 8:00 am ET to discuss the Company’s global collaboration agreement with Sanofi, as recently announced.
-
IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/29/2022
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing IgM antibodies, announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent developments.
-
IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19
2/9/2022
IGM Biosciences, Inc. today announced its progress in two Phase 1 clinical trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, for the treatment and prevention of COVID-19.
-
IGM Biosciences to Present at the Guggenheim 2022 Oncology Conference
2/3/2022
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the Guggenheim 2022 Oncology Conference.
-
IGM Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 10:30 a.m. EST.
-
IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting
12/11/2021
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced the presentation of clinical results from the Company’s Phase 1 trial evaluating IGM-2323, a novel bispecific IgM antibody targeting CD20 x CD3, at the 63rd American Society of Hematology Annual Meeting and Exposition.
-
IGM Biosciences to Collaborate on the Study of IgM and IgA Antibodies for the Prevention of Malaria
12/8/2021
IGM Biosciences, Inc. today announced a grant agreement with the Bill & Melinda Gates Foundation to fund the design, production, and evaluation of IgM and IgA antibodies for the potential prevention of malaria.